Prophylactic vaccination against human papillomavirus infection and disease in women: A systematic review of randomized controlled trials

CMAJ. Canadian Medical Association Journal

Volumn 177, Issue 5, 2007, Pages 469-479

  Rambout, Lisa ^a   Hopkins, Laura ^c   Hutton, Brian ^b   Fergusson, Dean ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM SULFATE; PHOSPHORYL LIPID A; VIRUS VACCINE;

ADJUVANT THERAPY; ARTICLE; BRONCHOSPASM; CHRONIC DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONDYLOMA; CONFIDENCE INTERVAL; DATA BASE; DRUG EFFICACY; EMBASE; FATIGUE; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GENITAL SYSTEM; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; INFORMATION PROCESSING; INJECTION SITE PAIN; INJECTION SITE REACTION; LONG TERM CARE; MEDLINE; META ANALYSIS; MORBIDITY; MORTALITY; MYALGIA; OUTCOME ASSESSMENT; PROPHYLAXIS; PRURITUS; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; REGISTER; RISK; SIDE EFFECT; SYSTEMATIC REVIEW; TEMPERATURE; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VALIDITY; VIRUS INFECTION; VIRUS ONCOGENE; VIRUS STRAIN; WART VIRUS;

EID: 34548451979     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.070948     Document Type: Article

References (26)

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
2. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl 3):S26-34.
3. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
4. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8.
5. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702.
6. Moher D, Cook DJ, Eastwood S, et al; QUOROM Group. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999;354:1896-900.
7. Pratt D, Goldenthal K, Geber A. Preventive human papillomavirus (HPV) vaccines - regulatory briefing document on endpoints. Vaccines and Related Biological Products Advisory Committee Meeting; 2001 Nov 28-29; Bethesda (MD). Available: www.fda.gov/ohrms/dockets/ac/01/briefing/3805b1_01.htm (accessed 2007 July 20).
8. Pagliusi SR, Teresa AM. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-78.
9. Booth A. "Brimful of STARLITE": toward standards for reporting literature searches. J Med Libr Assoc 2006;94:421-9,e205.
10. Glanville JM, Lefebvre C, Miles JN, et al. How to identify randomized controlled trials in MEDLINE: ten years on. J Med Libr Assoc 2006;94:130-6.
11. Wong SS, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc 2006;94:41-7.
12. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
13. Atkins D, Best D, Briss PA, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-4.
14. Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet 1997;350:185-6.
15. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77.
16. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
17. Garland SM, Hernandez-Avila M, Wheeler CM, et al; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
18. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
19. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
20. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
21. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
22. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70.
23. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
24. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66.
25. Gall SA, Teixeira J, Wheeler CM, et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine [abstract 4900]. American Association for Cancer Research annual meeting; 2007 Apr 14-16; Los Angeles.
26. Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22:663-70.